Windlas Biotech Limited — PPTs, 22-05-2025: Investor Presentation

1. Financial Highlights:

Windlas Biotech posted revenue of Rs 760 Cr, up 20% YoY. EBITDA rose 20% to Rs 94 Cr, with margins steady at 12.4%. PAT increased to Rs 61 Cr, representing an 8% margin despite higher depreciation from new injectable and Plant-2 expansions. EPS hit a record Rs 29.19. Operating cash flow stood at Rs 68 Cr, with working capital days at a lean 14 and liquidity of Rs 213 Cr. ROCE and ROE were strong at 25% and 23%. Revenue mix included 73% from Generic Formulations CDMO, 22% from Trade Generics & Institutional, and 5% from Exports.

2. Strategic Initiatives & Growth Drivers:

Capacity expansion is underway with Plant-5 injectable facility commissioned and Plant-2 extension ongoing. A capex of Rs 72 Cr is planned for FY25, alongside Plant-6 for oral solid dosage growth. The company is focusing on complex generics and chronic therapies, now 60% of the portfolio, backed by robust R&D with products rising from 3,190 to 4,340. Digital upgrades and compliance improvements support scalable quality leadership in the outsourced generics space.

3. Business Developments:

Customer base expanded to 757 CDMO clients, including seven of India’s top 10 pharma firms. Injectable facility approvals enable commercialization across multiple verticals. Export revenue grew 19% to Rs 33 Cr, boosted by dossier filings and approvals in South Africa and Europe. Trade generics now feature 400 brands, distributed through 1,095 stockists in 29 states.

4. Market Position & Competitive Advantage:

Windlas leads domestically in generic formulations CDMO with IP rights on 99% of products. Its WHO-GMP certified multi-plant setup offers cost advantages. Strength in complex generics, chronic therapy focus, quality systems, and customer relationships differentiate it in a fragmented market.

5. Investor Implications:

Robust growth, net debt-free balance sheet, and strategic capacity additions indicate positive growth potential. Leadership in complex generics and broadening clientele reduce concentration risks. Execution on capacity ramp-up, product launches, and export expansion will be key momentum drivers. Commitment to dividends adds to shareholder appeal.